On November 13, Legend Biotech fell 5.02% in Regular Trading, trading at $18.56 per share, with turnover of $66.8695 million.
The clearest catalyst was post-earnings analyst target-price cuts after the company reported third-quarter results that showed profit improvement but slightly missed revenue expectations.
Legend Biotech reported third-quarter net profit of $51.7 million, versus a loss a year earlier, while CARVYKTI net sales rose 36% year over year to about $710 million. However, quarterly revenue was $359.5 million, below the roughly $361.5 million market expectation. After the release, RBC cut its target price to $50 from $56 while maintaining Outperform; Morgan Stanley lowered its target to $43; and Oppenheimer reduced its target to $25. RBC still said Carvykti is positioned to sustain growth into 2027, but the immediate market reaction reflected the revenue shortfall and lowered valuation assumptions.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments